Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for obesity and type 2 diabetes, have demonstrated pleiotropic benefits that include reductions in systemic inflammation, improvement of myocardial energetics, and attenuation of adverse structural remodeling. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.